LifeMD

LifeMD, Inc. is an American telehealth company operating a subscription-oriented virtual-care platform. Its service gives patients access to online consultations with physicians and nurse practitioners, with treatment plans and prescription medicines provided when clinically appropriate. The company’s model combines digital intake, remote clinician visits, ongoing patient support, and medication fulfillment, positioning LifeMD between conventional primary care, direct-to-consumer healthcare, and digital pharmacy services. The business traces its corporate history to ImmuDyne, Inc., which was founded in 1994 and completed an initial public offering in 2001. The company later shifted its identity and commercial focus toward direct-to-consumer digital health. In 2018 it adopted the name Conversion Labs, Inc., and Justin Schreiber became chief executive officer. In 2020 the company changed its name to LifeMD and began using the LFMD ticker, reflecting the development of a broader virtual-care brand rather than a single-product consumer-health business. LifeMD’s service scope has included general virtual medical consultations and treatment programs delivered through its online platform. A major area of expansion has been weight management. In June 2023, the company announced a program under which eligible patients could seek prescriptions for GLP-1 medicines after a virtual clinical assessment and satisfaction of applicable requirements. The initiative placed LifeMD within the rapidly growing digital weight-management market, where telehealth providers compete on clinician access, convenience, medication availability, and patient-support services. The company’s weight-management strategy also included a relationship with Medifast. LifeMD began a pilot program with the health and wellness company, and the two companies subsequently announced a partnership intended to connect their respective customer bases. Medifast also made a $20 million investment in LifeMD in 2023. In 2024, LifeMD expanded its payment and access model by introducing acceptance of private health insurance, a step that broadened the potential customer base beyond entirely self-paying subscribers. In 2025, LifeMD continued to emphasize branded obesity-treatment access. In March it announced an arrangement to provide self-paying patients access to Eli Lilly’s Zepbound through a pharmacy partner associated with LillyDirect, including discounted cash-pay vials. Later reporting described a separate arrangement involving Novo Nordisk’s Wegovy and discounted access through the LifeMD platform. These developments contributed to heightened investor attention and a sharp movement in the company’s stock during 2025, although the business remained exposed to prescription supply, regulatory, reimbursement, and competition risks. LifeMD also pursued specialty-care expansion. In April 2025 it acquired Optimal Human Health MD, a virtual women’s-health provider. The acquisition was intended to establish or strengthen a platform covering hormone health, metabolism, and bone density, extending the company beyond general telehealth and weight management. The company has supplemented its operating expansion with changes in governance and corporate scale. In September 2022, former Louisiana governor Bobby Jindal joined its board of directors. LifeMD reported first-quarter 2025 revenue of $65.7 million, representing a 49 percent year-over-year increase for that quarter. Because LifeMD is publicly traded, its strategy, growth rate, and partnerships are subject to continuing disclosure and market scrutiny. Its current positioning is that of a U.S.-focused digital healthcare platform combining remote clinician access, prescription treatment, specialty programs, and consumer-oriented care pathways.

LifeMD’s corporate lineage begins with ImmuDyne, Inc., a company founded in 1994 that completed an initial public offering in 2001. The business later underwent a substantial change in identity and commercial direction. In 2018 it became Conversion Labs, Inc., with Justin Schreiber appointed chief executive officer. The rebranding reflected a move toward direct-to-consumer health products and services. In 2020, Conversion Labs changed its corporate name to LifeMD and began trading under the LFMD ticker. The new name emphasized a broader digital-health proposition: connecting patients with physicians and nurse practitioners through online consultations and supporting treatment with prescription medicines where clinically appropriate. Rather than operating as a conventional hospital or clinic network, LifeMD built its proposition around remote access, online enrollment, clinician evaluation, treatment plans, and recurring patient relationships. Governance and market development continued in 2022. In September of that year, former Louisiana governor Bobby Jindal joined the company’s board. The company’s most prominent expansion phase began in 2023, when it entered the digital weight-management market. In June, LifeMD announced a program allowing eligible patients to be considered for GLP-1 medicines following a virtual appointment with a clinician and completion of the relevant requirements. This gave the company exposure to a rapidly expanding category in which telehealth operators provide assessment, prescribing, and patient support around obesity treatments. LifeMD’s weight-management strategy was complemented by its relationship with Medifast. The companies began a pilot program and later announced a partnership to connect customers from both businesses. Medifast also invested $20 million in LifeMD. The relationship linked LifeMD’s virtual medical infrastructure with Medifast’s established health and wellness customer base, although the available reference material does not establish the full long-term commercial outcome of the arrangement. In 2024, LifeMD introduced acceptance of private health insurance. This represented a shift from a purely direct-pay or subscription-centered model toward a wider range of potential payment arrangements and could make selected services more accessible to insured patients. The available material does not specify the complete list of insurers, services, or geographic limitations. The company’s 2025 activity centered on obesity medicines and specialty-care growth. In March, LifeMD announced an agreement to offer Eli Lilly’s Zepbound to self-paying patients through a pharmacy partner associated with LillyDirect, including discounted cash-pay vials. Later in 2025, an arrangement involving Novo Nordisk’s Wegovy provided another discounted access route through the LifeMD platform. These developments helped draw substantial market attention and were associated with a surge in the company’s stock, though the reference material does not provide a verified price figure. In April 2025, LifeMD acquired Optimal Human Health MD, a virtual provider focused on women’s health. LifeMD described the transaction as creating a foundation for care related to hormone health, metabolism, and bone density. The acquisition broadened the company’s specialty-care ambitions beyond general telehealth and weight management. Operationally, LifeMD reported first-quarter 2025 revenue of $65.7 million, a 49 percent year-over-year increase. The company’s development illustrates the evolution of a publicly traded corporate shell and consumer-health business into a branded telehealth platform. Its principal challenges include maintaining clinical and regulatory compliance, managing prescription availability, securing sustainable reimbursement and pharmacy relationships, and differentiating its digital services in a competitive virtual-care market.

• 2025

  Obesity-medicine access and specialty expansion

  [1]LifeMDen.wikipedia.org

  LifeMD announces Zepbound and Wegovy access arrangements and acquires Optimal Human Health MD.

• 2024

  Private insurance acceptance introduced

  [1]LifeMDen.wikipedia.org

  LifeMD adds private health insurance acceptance to its access and payment model.

• 2023

  Weight-management program announced

  [1]LifeMDen.wikipedia.org

  LifeMD launches a virtual weight-management program that can evaluate eligible patients for GLP-1 prescriptions.

• 2022

  Bobby Jindal joins the board

  [1]LifeMDen.wikipedia.org

  Former Louisiana governor Bobby Jindal is appointed to LifeMD’s board of directors.

• 2020

  LifeMD name and ticker adopted

  [1]LifeMDen.wikipedia.org

  The company changes its name to LifeMD and begins using the LFMD ticker.

• 2018

  Conversion Labs rebrand

  [1]LifeMDen.wikipedia.org

  The company adopts the name Conversion Labs, Inc., and Justin Schreiber becomes chief executive officer.

• 2001

  Initial public offering

  [1]LifeMDen.wikipedia.org

  ImmuDyne completes its initial public offering.

• 1994

  Corporate predecessor is founded

  [1]LifeMDen.wikipedia.org

  The company’s corporate predecessor, ImmuDyne, Inc., is founded.

A U.S. consumer-focused telehealth platform emphasizing convenient virtual clinician access, prescription treatment, weight management, and expanding specialty-care programs.

• Telehealth service

  Virtual medical consultations

  LifeMD’s core service connects subscribers or patients with physicians and nurse practitioners through virtual appointments. Clinicians assess reported symptoms and health needs remotely and may recommend treatment or prescription medicines when appropriate. The service is designed around convenience and remote access rather than in-person clinic visits.

• Digital weight management · 2023

  LifeMD weight-management program

  Introduced in 2023, the program provides a virtual clinical pathway for patients seeking medical weight-management support. After an online appointment and assessment of eligibility, a clinician may prescribe GLP-1 medication when medically appropriate and permitted. The offering combines remote evaluation with ongoing digital care and prescription access.

• Prescription medication access · 2025

  Zepbound access

  LifeMD announced an arrangement for qualifying self-paying patients to obtain Eli Lilly’s Zepbound through a pharmacy partner associated with LillyDirect. The arrangement focused on discounted cash-pay vials and extended LifeMD’s role from virtual assessment into branded obesity-medication access.

• Prescription medication access · 2025

  Wegovy access

  LifeMD entered an arrangement involving Novo Nordisk’s Wegovy, offering a discounted access route through its telehealth platform. The offering forms part of the company’s strategy to support medically supervised weight management and connect patients with branded GLP-1 treatment.

• Specialty telehealth · 2025

  Women’s health virtual care

  Following the acquisition of Optimal Human Health MD, LifeMD expanded its specialty-care platform into women’s health, with an intended focus on hormone health, metabolism, and bone density. The acquisition provides a foundation for virtual programs addressing longer-term and age-related health needs.

• 2025

  Offer discounted cash-pay Zepbound accessProduct launch

  Background

  LifeMD was increasing its role in branded obesity-treatment access.

  Action taken

  The company signed an agreement involving a LillyDirect pharmacy partner to offer Zepbound vials at discounts to qualifying self-paying patients.

  Aftermath

  The arrangement strengthened LifeMD’s position in digital weight management and attracted market attention.

  Source

• 2025

  Acquire Optimal Human Health MDM&A

  Background

  LifeMD wanted to broaden its specialty-care platform beyond general telehealth and weight management.

  Action taken

  LifeMD acquired Optimal Human Health MD, a virtual women’s-health provider.

  Aftermath

  The transaction established a foundation for virtual services focused on hormone health, metabolism, and bone density.

  Source

• 2024

  Accept private health insuranceStrategy

  Background

  LifeMD was broadening access beyond a strictly self-pay and subscription-oriented model.

  Action taken

  The company introduced acceptance of private health insurance.

  Aftermath

  The change potentially expanded the addressable patient base, although the available reference does not specify the full coverage scope.

  Source

• 2023

  Enter virtual GLP-1 weight managementProduct launch

  Background

  Demand for medically supervised digital weight-management services and GLP-1 medicines was increasing.

  Action taken

  LifeMD launched a program allowing eligible patients to receive virtual clinical evaluation for potential GLP-1 prescriptions.

  Aftermath

  Weight management became a central growth and partnership area for the company.

  Source

• 2023

  Partner with and receive investment from MedifastM&A

  Background

  LifeMD sought to expand the reach of its virtual-care and weight-management services.

  Action taken

  LifeMD piloted a program with Medifast, later formalizing a customer-connection partnership; Medifast invested $20 million in LifeMD.

  Aftermath

  The companies gained a commercial relationship linking Medifast’s customer base with LifeMD’s digital clinical services.

  Investment. $20 million (2023)

  Source

• 2020

  Adopt the LifeMD identityStrategy

  Background

  The company sought to present a broader digital-health and virtual-care proposition.

  Action taken

  Conversion Labs changed its name to LifeMD and began using the LFMD ticker.

  Aftermath

  The LifeMD name became the public-facing identity for the company’s telehealth platform.

  Source

• 2018

  Rebrand as Conversion LabsStrategy

  Background

  The corporate predecessor was repositioning its business toward direct-to-consumer health activity.

  Action taken

  The company changed its name from ImmuDyne, Inc. to Conversion Labs, Inc. and appointed Justin Schreiber as chief executive officer.

  Aftermath

  The rebrand preceded the later development of the LifeMD telehealth identity.

  Source

• 2025

  LifeMD offers cash-pay access to Zepbound through a LillyDirect pharmacy partner[1]LifeMDen.wikipedia.org

  Product launch · Pricing

  LifeMD announced an arrangement intended to let qualifying self-paying patients obtain discounted Zepbound vials through a pharmacy partner associated with LillyDirect.

• 2025

  LifeMD reports first-quarter revenue growth[1]LifeMDen.wikipedia.org

  Other

  For the first quarter of 2025, LifeMD reported revenue of $65.7 million, up 49 percent from the comparable prior-year period.

• 2025

  LifeMD acquires Optimal Human Health MD[1]LifeMDen.wikipedia.org

  M&A

  LifeMD acquired the virtual women’s-health provider Optimal Human Health MD to expand into hormone health, metabolism, and bone-density care.

• 2025

  LifeMD adds Wegovy access to its weight-management platform[1]LifeMDen.wikipedia.org

  Product launch · Pricing

  LifeMD entered an arrangement involving Novo Nordisk’s Wegovy and discounted access through its platform; the announcement was associated with increased investor attention and stock volatility.

• 2024

  LifeMD adds private health insurance acceptance[1]LifeMDen.wikipedia.org

  Other

  LifeMD began accepting private health insurance, broadening its access and payment model beyond exclusively self-funded care.

• 2023

  LifeMD launches a GLP-1-oriented weight-management program[1]LifeMDen.wikipedia.org

  Product launch

  The company introduced a virtual weight-management program through which eligible patients could be evaluated by clinicians for potential GLP-1 prescriptions.

• 2023

  LifeMD and Medifast expand their relationship[1]LifeMDen.wikipedia.org

  M&A · Other

  LifeMD piloted a program with Medifast, followed by a partnership designed to connect the companies’ customer bases. Medifast also invested $20 million in LifeMD.

• 2022

  LifeMD appoints Bobby Jindal to its board[1]LifeMDen.wikipedia.org

  Leadership change

  LifeMD announced that former Louisiana governor Bobby Jindal had joined its board of directors.

1. 1LifeMDen.wikipedia.org
2. 2LifeMD Partners With Prescryptive Health, Expanding Convenience and Affordability for Patientsfinance.yahoo.com